Bristol-Myers Squibb Company (BMY)

Jefferies Group analyst J. Holford now expects that the biopharmaceutical company will earn $2.86 per share for the year, up from their previous estimate of $2.79.

With a total market value of $0, Bristol-Myers Squibb Co has price-earnings ratio of 20.16 with a one year low of $46.01 and a one year high of $77.12.

Now, the FactSet Research estimate calls for Q1 2017 earnings of US$0.73. Bristol-Myers Squibb had a net margin of 22.94% and a return on equity of 31.39%. The business had revenue of $5.24 billion for the quarter, compared to the consensus estimate of $5.14 billion.

Its sales stood at -1.80% a year on average in the period of last five years. Bristol-Myers Squibb's quarterly revenue was up 22.3% on a year-over-year basis. The correct version of this article can be viewed at If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & worldwide copyright and trademark legislation. Moving average strategies are also popular and can be tailored to any time frame, suiting both long term investors and short-term traders. Analysts anticipate that Bristol-Myers Squibb Co will post $2.80 earnings per share for the current fiscal year. BMO Capital Markets reiterated a "market perform" rating and issued a $45.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, April 4th. The stock of Bristol-Myers Squibb Co (NYSE:BMY) earned "Outperform" rating by Credit Suisse on Monday, May 9.

U.S. based company, Bristol-Myers Squibb Company (BMY)'s latest closing price distance was at -7.48% from the average-price of 200 days while it maintained a distance from the 50 Day Moving Average at -2.61% and -3.46% compared with the 20 Day Moving Average. ABR value is precisely based on brokerage recommendations, where out of 13 brokerage recommendations 6 rate Bristol-Myers Squibb Co (NYSE:BMY) stock a Strong Buy, 1 rate the stocks of the company a Buy, 6 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Also, the current price highlights a discount of 36.25% to analysts' high consensus price target.

Shares of Bristol-Myers Squibb Co (NYSE:BMY) opened at 52.99 on Thursday.

Turning to Unit Corporation (NYSE:UNT), its shares were trading at $24.22 a gain of $0.34, on the trading floor. The company's 50-day moving average is $55.74 and its 200-day moving average is $54.67. The company has a market capitalization of $88.64 billion, a price-to-earnings ratio of 20.00 and a beta of 1.00.

More news: German investigators check further claim for Dortmund attack

Several research analysts have recently weighed in on BMY shares. Security Asset Management's holdings in Bristol-Myers Squibb were worth $662,000 at the end of the most recent quarter. With 1.92M avg volume, 4 days are for Nielsen Holdings Plc (NYSE:NLSN)'s short sellers to cover NLSN's short positions. 1 Month Ago, shares have been suggested as BUY from 10 and 1 issued SELL signal for the company's stock.12 told as a HOLD the stock. Sabby Management stated it has 0.98% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). CA boosted its stake in shares of Bristol-Myers Squibb by 21.0% in the third quarter.

Rhenman & Partners Asset Management Ab decreased Kite Pharma Inc (NASDAQ:KITE) stake by 10,000 shares to 80,000 valued at $3.59 million in 2016Q4. Webster Bank N.A. now owns 43,573 shares of the biopharmaceutical company's stock valued at $2,349,000 after buying an additional 570 shares in the last quarter.

11/07/2016 - Bristol-Myers Squibb Company had its "buy" rating reiterated by analysts at Citigroup. They now have a Dollars 60 price target on the stock.

The number of shares now held by investors is 1.65 Billion. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

In other Bristol-Myers Squibb news, EVP Sandra Leung sold 92,405 shares of the company's stock in a transaction dated Monday, March 6th. The stock was trading on below-average volume. Following the completion of the sale, the executive vice president now owns 488,063 shares in the company, valued at $27,829,352.26. The disclosure for this purchase can be found here.

Bristol-Myers Squibb Co (NYSE:BMY) performance over the past one year plunged -18.65% whereas its year to date (YTD) performance indicated a bearish trend of -8.08%.

The firm also recently declared a quarterly dividend, which will be paid on Monday, May 1st. Shareholders of record on Friday, April 7th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 2.95%.